Lexicon Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, LXRX, Lexicon Pharmaceuticals Inc, priceseries

Lexicon Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
2.10
Close
2.12
High
2.18
Low
2.06
Previous Close
2.13
Daily Price Gain
-0.01
YTD High
3.99
YTD High Date
Jan 4, 2022
YTD Low
2.00
YTD Low Date
Mar 2, 2022
YTD Price Change
-1.77
YTD Gain
-45.50%
52 Week High
7.43
52 Week High Date
Mar 10, 2021
52 Week Low
2.00
52 Week Low Date
Mar 2, 2022
52 Week Price Change
-4.62
52 Week Gain
-68.55%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 6. 2017
14.94
Jun 27. 2017
17.14
15 Trading Days
14.74%
Link
LONG
May 3. 2018
8.30
May 23. 2018
9.71
14 Trading Days
16.93%
Link
LONG
May 29. 2018
9.84
Jun 25. 2018
12.76
19 Trading Days
29.66%
Link
LONG
Apr 26. 2019
5.96
Apr 29. 2019
6.36
1 Trading Days
6.63%
Link
LONG
May 1. 2019
5.97
May 13. 2019
6.42
8 Trading Days
7.62%
Link
LONG
Sep 6. 2019
1.38
Sep 30. 2019
2.98
16 Trading Days
116.29%
Link
LONG
Oct 22. 2019
3.40
Nov 7. 2019
3.69
12 Trading Days
8.59%
Link
LONG
Dec 4. 2019
3.77
Dec 17. 2019
4.67
9 Trading Days
23.95%
Link
LONG
Apr 9. 2020
1.88
Apr 16. 2020
2.00
4 Trading Days
6.39%
Link
LONG
Nov 9. 2020
1.16
Dec 1. 2020
1.46
15 Trading Days
25.99%
Link
LONG
Dec 4. 2020
1.58
Dec 29. 2020
3.19
16 Trading Days
101.90%
Link
LONG
Jan 7. 2021
3.67
Feb 10. 2021
8.41
23 Trading Days
129.10%
Link
LONG
Aug 23. 2021
3.88
Sep 13. 2021
4.63
14 Trading Days
19.43%
Link
Company Information
Stock Symbol
LXRX
Exchange
NasdaqGS
Company URL
http://www.lexpharma.com
Company Phone
2818633000
CEO
Lonnel Coats
Headquarters
Texas
Business Address
8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS, TX 77381
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001062822
About

Lexicon Pharmaceuticals, Inc. operates as a biopharmaceutical company which focuses on the development of breakthrough treatments for human disease. It has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Description

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain. The company has license and collaboration agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading